The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -8,228 |
| Depreciation | 24 |
| Reduction in the carrying amount of right-of-use assets | 481 |
| Share-based compensation | 430 |
| Allowance for doubtful accounts | 0 |
| Accounts receivable | 20 |
| Prepaid expenses | -35 |
| Accounts payable | 163 |
| Accrued expenses and other current liabilities | 179 |
| Operating lease liability | -500 |
| Net cash used in operating activities | -7,436 |
| Purchase of property and equipment | 7 |
| Net cash used in investing activities | -7 |
| Exercise of common stock warrants | 5 |
| Taxes paid related to net share settlement of equity awards | 197 |
| Proceeds from sales of common stock | 8,690 |
| Issuance costs of sale of common stock | 930 |
| Net cash provided by financing activities | 7,568 |
| Net change in cash and cash equivalents | 125 |
| Cash and cash equivalents at beginning of year | 2,371 |
| Cash and cash equivalents at end of period | 2,496 |
BioCardia, Inc. (BCDA)
BioCardia, Inc. (BCDA)